Clinical Trial Update: Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Amsterdam UMC evaluating the combination of paclitaxel and trastuzumab in patients with EGFR-mutated, HER2-expressing non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: NSCLC, HER2-expression | Phase 2 | Status: UNKNOWN